カテゴリー： QYResearch, 世界

悪性神経膠腫治療法の世界市場：規模・現状・予測2019-2025

【英語タイトル】Global Malignant Glioma Therapeutics Market Size, Status and Forecast 2019-2025

QYResearchが出版した調査資料（DATA909X18662）・商品コード：DATA909X18662
・発行会社（調査会社）：QYResearch
・発行日：2019年11月25日（※2024年版があります。お問い合わせください）
・ページ数：98
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,900 ⇒換算￥577,200見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD5,850 ⇒換算￥865,800見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD7,800 ⇒換算￥1,154,400見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・郵送（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
※当調査レポートでは、悪性神経膠腫治療法の世界市場について調査・分析し、悪性神経膠腫治療法の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別（化学療法、放射線療法、標的療法）、用途別（大人、子供）、地域別（北米、ヨーロッパ、中国、日本国内、東南アジア、インド、中南米）に区分して市場規模を算出しました。


・レポートの概要
・世界の悪性神経膠腫治療法市場動向
・主要企業別マーケットシェア
・悪性神経膠腫治療法の種類別市場規模2014-2019
（化学療法、放射線療法、標的療法）
・悪性神経膠腫治療法の用途別市場規模2014-2019
（大人、子供）
・悪性神経膠腫治療法の北米市場：主要企業・種類別/用途別市場規模
・悪性神経膠腫治療法のヨーロッパ市場：主要企業・種類別/用途別市場規模
・悪性神経膠腫治療法の中国市場：主要企業・種類別/用途別市場規模
・悪性神経膠腫治療法の日本国内市場：主要企業・種類別/用途別市場規模
・悪性神経膠腫治療法の東南アジア市場：主要企業・種類別/用途別市場規模
・悪性神経膠腫治療法のインド市場：主要企業・種類別/用途別市場規模
・悪性神経膠腫治療法の中南米市場：主要企業・種類別/用途別市場規模
・主要企業のプロフィール
（Merck、Roche、Arbor Pharmaceuticals、Pfizer、AbbVie、Amgen、Bristol-Myers Squibb、Sun Pharmaceuticals、Teva、Emcure）
・悪性神経膠腫治療法の市場規模予測2019-2025
（種類別、用途別、地域別市場予測）
・アナリストの観点・結論
...
【レポートの概要】

Malignant glioma, a tumor derived from the nerve epithelium, is generally referred to as glioma, accounting for 40-50% of brain tumors, and is the most common intracranial malignant tumor.In 2018, the global Malignant Glioma Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Malignant Glioma Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Malignant Glioma Therapeutics development in North America, Europe and Asia-Pacific.

The key players covered in this study
Merck
Roche
Arbor Pharmaceuticals
Pfizer
AbbVie
Amgen
Bristol-Myers Squibb
Sun Pharmaceuticals
Teva
Emcure

Market segment by Type, the product can be split into
Chemotherapy
Radiotherapy
Targeted therapy

Market segment by Application, split into
Adult
Children

Market segment by Regions/Countries, this report covers
North America
Europe
Asia-Pacific

The study objectives of this report are:
To analyze global Malignant Glioma Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Malignant Glioma Therapeutics development in North America, Europe and Asia-Pacific.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Malignant Glioma Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

【レポートの目次】

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Malignant Glioma Therapeutics Market Size Growth Rate by Type (2014-2025)
1.4.2 Chemotherapy
1.4.3 Radiotherapy
1.4.4 Targeted therapy
1.5 Market by Application
1.5.1 Global Malignant Glioma Therapeutics Market Share by Application (2019-2025)
1.5.2 Adult
1.5.3 Children
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Malignant Glioma Therapeutics Market Size
2.2 Malignant Glioma Therapeutics Growth Trends by Regions
2.2.1 Malignant Glioma Therapeutics Market Size by Regions (2019-2025)
2.2.2 Malignant Glioma Therapeutics Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis

3 Market Share by Key Players
3.1 Malignant Glioma Therapeutics Market Size by by Players
3.1.1 Global Malignant Glioma Therapeutics Revenue by by Players (2014-2019)
3.1.2 Global Malignant Glioma Therapeutics Revenue Market Share by by Players (2014-2019)
3.1.3 Global Malignant Glioma Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2 Malignant Glioma Therapeutics Key Players Head office and Area Served
3.3 Key Players Malignant Glioma Therapeutics Product/Solution/Service
3.4 Date of Enter into Malignant Glioma Therapeutics Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Malignant Glioma Therapeutics Market Size by Type (2014-2019)
4.2 Global Malignant Glioma Therapeutics Market Size by Application (2014-2019)

5 North America
5.1 North America Malignant Glioma Therapeutics Market Size (2014-2019)
5.2 Malignant Glioma Therapeutics Key Players in North America
5.3 North America Malignant Glioma Therapeutics Market Size by Type
5.4 North America Malignant Glioma Therapeutics Market Size by Application

6 Europe
6.1 Europe Malignant Glioma Therapeutics Market Size (2014-2019)
6.2 Malignant Glioma Therapeutics Key Players in Europe
6.3 Europe Malignant Glioma Therapeutics Market Size by Type
6.4 Europe Malignant Glioma Therapeutics Market Size by Application

7 Asia-Pacific
7.1 Asia-Pacific Malignant Glioma Therapeutics Market Size (2014-2019)
7.2 Malignant Glioma Therapeutics Key Players in Asia-Pacific
7.3 Asia-Pacific Malignant Glioma Therapeutics Market Size by Type
7.4 Asia-Pacific Malignant Glioma Therapeutics Market Size by Application

8 International Players Profiles
8.1 Merck
8.1.1 Merck Company Details
8.1.2 Company Description and Business Overview
8.1.3 Malignant Glioma Therapeutics Introduction
8.1.4 Merck Revenue in Malignant Glioma Therapeutics Business (2014-2019))
8.1.5 Merck Recent Development
8.2 Roche
8.2.1 Roche Company Details
8.2.2 Company Description and Business Overview
8.2.3 Malignant Glioma Therapeutics Introduction
8.2.4 Roche Revenue in Malignant Glioma Therapeutics Business (2014-2019)
8.2.5 Roche Recent Development
8.3 Arbor Pharmaceuticals
8.3.1 Arbor Pharmaceuticals Company Details
8.3.2 Company Description and Business Overview
8.3.3 Malignant Glioma Therapeutics Introduction
8.3.4 Arbor Pharmaceuticals Revenue in Malignant Glioma Therapeutics Business (2014-2019)
8.3.5 Arbor Pharmaceuticals Recent Development
8.4 Pfizer
8.4.1 Pfizer Company Details
8.4.2 Company Description and Business Overview
8.4.3 Malignant Glioma Therapeutics Introduction
8.4.4 Pfizer Revenue in Malignant Glioma Therapeutics Business (2014-2019)
8.4.5 Pfizer Recent Development
8.5 AbbVie
8.5.1 AbbVie Company Details
8.5.2 Company Description and Business Overview
8.5.3 Malignant Glioma Therapeutics Introduction
8.5.4 AbbVie Revenue in Malignant Glioma Therapeutics Business (2014-2019)
8.5.5 AbbVie Recent Development
8.6 Amgen
8.6.1 Amgen Company Details
8.6.2 Company Description and Business Overview
8.6.3 Malignant Glioma Therapeutics Introduction
8.6.4 Amgen Revenue in Malignant Glioma Therapeutics Business (2014-2019)
8.6.5 Amgen Recent Development
8.7 Bristol-Myers Squibb
8.7.1 Bristol-Myers Squibb Company Details
8.7.2 Company Description and Business Overview
8.7.3 Malignant Glioma Therapeutics Introduction
8.7.4 Bristol-Myers Squibb Revenue in Malignant Glioma Therapeutics Business (2014-2019)
8.7.5 Bristol-Myers Squibb Recent Development
8.8 Sun Pharmaceuticals
8.8.1 Sun Pharmaceuticals Company Details
8.8.2 Company Description and Business Overview
8.8.3 Malignant Glioma Therapeutics Introduction
8.8.4 Sun Pharmaceuticals Revenue in Malignant Glioma Therapeutics Business (2014-2019)
8.8.5 Sun Pharmaceuticals Recent Development
8.9 Teva
8.9.1 Teva Company Details
8.9.2 Company Description and Business Overview
8.9.3 Malignant Glioma Therapeutics Introduction
8.9.4 Teva Revenue in Malignant Glioma Therapeutics Business (2014-2019)
8.9.5 Teva Recent Development
8.10 Emcure
8.10.1 Emcure Company Details
8.10.2 Company Description and Business Overview
8.10.3 Malignant Glioma Therapeutics Introduction
8.10.4 Emcure Revenue in Malignant Glioma Therapeutics Business (2014-2019)
8.10.5 Emcure Recent Development

9 Market Forecast 2019-2025
9.1 Market Size Forecast by Product (2019-2025)
9.2 Market Size Forecast by Application (2019-2025)
9.3 Market Size Forecast by Regions
9.4 North America
9.5 Europe
9.6 Asia-Pacific

10 Analyst’s Viewpoints/Conclusions

11 Appendix
11.1 Research Methodology
11.1.1 Methodology/Research Approach
11.1.1.1 Research Programs/Design
11.1.1.2 Market Size Estimation
11.1.1.3 Market Breakdown and Data Triangulation
11.1.2 Data Source
11.1.2.1 Secondary Sources
11.1.2.2 Primary Sources
11.2 Disclaimer
11.3 Author Details

List of Tables and Figures

Table Malignant Glioma Therapeutics Key Market Segments
Table Key Players Malignant Glioma Therapeutics Covered
Table Global Malignant Glioma Therapeutics Market Size Growth Rate by Type 2018-2025 (Million US$)
Figuer Chemotherapy Figures
Table Key Players of Chemotherapy
Figuer Radiotherapy Figures
Table Key Players of Radiotherapy
Figuer Targeted therapy Figures
Table Key Players of Targeted therapy
Table Global Malignant Glioma Therapeutics Market Size Growth by Application 2019-2025 (Million US$)
Figure Global Malignant Glioma Therapeutics Market Share by Application in 2018 & 2025
Figure Adult Case Studies
Figure Children Case Studies
Figure Malignant Glioma Therapeutics Report Years Considered
Figure Global Malignant Glioma Therapeutics Market Size and Growth Rate 2014-2025 (Million US$)
Table Global Malignant Glioma Therapeutics Market Size by Regions 2019-2025 (Million US$)
Table Global Malignant Glioma Therapeutics Market Size by Regions 2019-2025 (Million US$)
Table Global Malignant Glioma Therapeutics Market Share by Regions 2014-2019
Figure Global Malignant Glioma Therapeutics Market Share by Regions 2014-2019
Figure Global Malignant Glioma Therapeutics Market Share by Regions in 2018
Table Market Top Trends
Table Key Drivers: Impact Analysis (2019-2025)
Table Key Challenges
Figure PORTER'S FIVE FORCES ANALYSIS
Table Global Malignant Glioma Therapeutics Revenue by by Players (2014-2019) (Million US$)
Table Global Malignant Glioma Therapeutics Market Share by by Players (2014-2019)
Figure Global Malignant Glioma Therapeutics Market Share by by Players in 2018
Table Global Malignant Glioma Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table Key Players Head office and Area Served
Table Key Players Malignant Glioma Therapeutics Product/Solution/Service
Table Date of Enter into Malignant Glioma Therapeutics Market
Table Mergers & Acquisitions, Expansion Plans
Table Global Malignant Glioma Therapeutics Market Size by Type (2014-2019) (Million US$)
Table Global Malignant Glioma Therapeutics Market Size Share by Type (2014-2019)
Figure Global Malignant Glioma Therapeutics Market Size Market Share by Type (2014-2019)
Table Global Malignant Glioma Therapeutics Market Size by Application (2014-2019) (Million US$)
Table Global Malignant Glioma Therapeutics Market Size Share by Application (2014-2019)
Figure Global Malignant Glioma Therapeutics Market Size Market Share by Application (2014-2019)
Figure Global Malignant Glioma Therapeutics Revenue Market Share by Application in 2018
Figure North America Malignant Glioma Therapeutics Market Size 2014-2019 (Million US$)
Table North America Key Players Malignant Glioma Therapeutics Revenue (2018-2019) (Million US$)
Table North America Key Players Malignant Glioma Therapeutics Market Share (2018-2019)
Table North America Malignant Glioma Therapeutics Market Size by Type 2014-2019 (Million US$)
Table North America Malignant Glioma Therapeutics Market Share by Type 2014-2019
Table North America Malignant Glioma Therapeutics Market Size by Application 2014-2019 (Million US$)
Table North America Malignant Glioma Therapeutics Market Share by Application 2014-2019
Figure Europe Malignant Glioma Therapeutics Market Size 2014-2019 (Million US$)
Table Europe Key Players Malignant Glioma Therapeutics Revenue (2018-2019) (Million US$)
Table Europe Key Players Malignant Glioma Therapeutics Market Share (2018-2019)
Table Europe Malignant Glioma Therapeutics Market Size by Type 2014-2019 (Million US$)
Table Europe Malignant Glioma Therapeutics Market Share by Type 2014-2019
Table Europe Malignant Glioma Therapeutics Market Size by Application 2014-2019 (Million US$)
Table Europe Malignant Glioma Therapeutics Market Share by Application 2014-2019
Figure Asia-Pacific Malignant Glioma Therapeutics Market Size 2014-2019 (Million US$)
Table Asia-Pacific Key Players Malignant Glioma Therapeutics Revenue (2018-2019) (Million US$)
Table Asia-Pacific Key Players Malignant Glioma Therapeutics Market Share (2018-2019)
Table Asia-Pacific Malignant Glioma Therapeutics Market Size by Type 2014-2019 (Million US$)
Table Asia-Pacific Malignant Glioma Therapeutics Market Share by Type 2014-2019
Table Asia-Pacific Malignant Glioma Therapeutics Market Size by Application 2014-2019 (Million US$)
Table Asia-Pacific Malignant Glioma Therapeutics Market Share by Application 2014-2019
Table Merck Company Details
Table Merck Revenue in Malignant Glioma Therapeutics Business 2014-2019 (Million US$)
Figure Merck Revenue Growth Rate in Malignant Glioma Therapeutics Business (2014-2019)
Table Merck Recent Development
Table Roche Company Details
Table Roche Revenue in Malignant Glioma Therapeutics Business 2014-2019 (Million US$)
Figure Roche Revenue Growth Rate in Malignant Glioma Therapeutics Business (2014-2019)
Table Roche Recent Development
Table Arbor Pharmaceuticals Company Details
Table Arbor Pharmaceuticals Revenue in Malignant Glioma Therapeutics Business 2014-2019 (Million US$)
Figure Arbor Pharmaceuticals Revenue Growth Rate in Malignant Glioma Therapeutics Business (2014-2019)
Table Arbor Pharmaceuticals Recent Development
Table Pfizer Company Details
Table Pfizer Revenue in Malignant Glioma Therapeutics Business 2014-2019 (Million US$)
Figure Pfizer Revenue Growth Rate in Malignant Glioma Therapeutics Business (2014-2019)
Table Pfizer Recent Development
Table AbbVie Company Details
Table AbbVie Revenue in Malignant Glioma Therapeutics Business 2014-2019 (Million US$)
Figure AbbVie Revenue Growth Rate in Malignant Glioma Therapeutics Business (2014-2019)
Table AbbVie Recent Development
Table Amgen Company Details
Table Amgen Revenue in Malignant Glioma Therapeutics Business 2014-2019 (Million US$)
Figure Amgen Revenue Growth Rate in Malignant Glioma Therapeutics Business (2014-2019)
Table Amgen Recent Development
Table Bristol-Myers Squibb Company Details
Table Bristol-Myers Squibb Revenue in Malignant Glioma Therapeutics Business 2014-2019 (Million US$)
Figure Bristol-Myers Squibb Revenue Growth Rate in Malignant Glioma Therapeutics Business (2014-2019)
Table Bristol-Myers Squibb Recent Development
Table Sun Pharmaceuticals Company Details
Table Sun Pharmaceuticals Revenue in Malignant Glioma Therapeutics Business 2014-2019 (Million US$)
Figure Sun Pharmaceuticals Revenue Growth Rate in Malignant Glioma Therapeutics Business (2014-2019)
Table Sun Pharmaceuticals Recent Development
Table Teva Company Details
Table Teva Revenue in Malignant Glioma Therapeutics Business 2014-2019 (Million US$)
Figure Teva Revenue Growth Rate in Malignant Glioma Therapeutics Business (2014-2019)
Table Teva Recent Development
Table Emcure Company Details
Table Emcure Revenue in Malignant Glioma Therapeutics Business 2014-2019 (Million US$)
Figure Emcure Revenue Growth Rate in Malignant Glioma Therapeutics Business (2014-2019)
Table Emcure Recent Development
Table Global Malignant Glioma Therapeutics Market Size by Regions (Million US$) 2019-2025
Figure Global Malignant Glioma Therapeutics Market Size Share by Regions (2019-2025)
Figure Global Malignant Glioma Therapeutics Market Size Share by Regions in 2025
Figure North America Malignant Glioma Therapeutics Market Size Forecast (2019-2025)(Million USD)
Figure Europe Malignant Glioma Therapeutics Market Size Forecast (2019-2025)(Million USD)
Figure Asia-Pacific Malignant Glioma Therapeutics Market Size Forecast (2019-2025)(Million USD)
Table Global Malignant Glioma Therapeutics Market Size by Product (2019-2025) (Million US$)
Figure Global Malignant Glioma Therapeutics Market Size by Product (2019-2025)
Figure Global Malignant Glioma Therapeutics Market Size by Product in 2025
Table Global Malignant Glioma Therapeutics Market Size by Application (2019-2025) (Million US$)
Figure Global Malignant Glioma Therapeutics Market Size by Application (2019-2025)
Figure Global Malignant Glioma Therapeutics Market Size by Application in 2025
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources


【掲載企業】

Merck、Roche、Arbor Pharmaceuticals、Pfizer、AbbVie、Amgen、Bristol-Myers Squibb、Sun Pharmaceuticals、Teva、Emcure

★調査レポート[悪性神経膠腫治療法の世界市場：規模・現状・予測2019-2025] (コード：DATA909X18662)販売に関する免責事項を必ずご確認ください。
★調査レポート[悪性神経膠腫治療法の世界市場：規模・現状・予測2019-2025]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 転移性悪性黒色腫療法の世界市場：規模・現状・予測2019-2025
    DATA909X18698 / QYResearch / 2019年11月25日 / ※当調査レポートでは、転移性悪性黒色腫療法の世界市場について調査・分析し、転移性悪性黒色腫療法の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別（免疫療法、標的療法、その他）、用途別（病院、医学研究機関、その他）、地域別（北米、ヨーロッパ、中国、日本国内、東南アジア、インド、中南米）に区分して市場規模を算出しました。 ・レポートの概要 ・世界の転移性悪性黒色腫療法市場動向 ・主要企業別マーケットシェア ・転移性悪性黒色腫療法の種類別市場規模2014-2019 （免疫療法、標的療法、その他） ・転移性悪性黒色腫療法の用途別市場規模2014-2019 （病院、医学研究機関、その他） ・転移性悪性黒色腫療法の北米市場：主要企業・種類別/用途別市場規模 ・転移性悪性黒色腫療法のヨーロッパ市場：主要企業・種類別/用途別市場規模...Heart metastatic malignant melanoma  is the late stage of tumor development.Treatment is mainly to alleviate symptoms and support the treatment of the whole body, such as anemia, edema, hypoproteinemia.For pleural or pericardial effusion should be punctured as soon as possible or catheter drainage, in order to reduce the cardiopulmonary compression.Chemotherapy and immunotherapy can be used in patients with better systemic status, but malignant melanoma is not sensitive to the former, while the latter has a certain effect on enhancing the patient's immunity.Radiotherapy can be used as an experimental therapy and can also confirm the presence or absence of cardiac metastasis.Arrhythmias...
  • 悪性腹水治療の世界市場：規模・現状・予測2019-2025
    DATA909X18661 / QYResearch / 2019年11月25日 / ※当調査レポートでは、悪性腹水治療の世界市場について調査・分析し、悪性腹水治療の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別（穿刺、化学療法、外科的治療）、用途別（病院、クリニック、その他）、地域別（北米、ヨーロッパ、中国、日本国内、東南アジア、インド、中南米）に区分して市場規模を算出しました。 ・レポートの概要 ・世界の悪性腹水治療市場動向 ・主要企業別マーケットシェア ・悪性腹水治療の種類別市場規模2014-2019 （穿刺、化学療法、外科的治療） ・悪性腹水治療の用途別市場規模2014-2019 （病院、クリニック、その他） ・悪性腹水治療の北米市場：主要企業・種類別/用途別市場規模 ・悪性腹水治療のヨーロッパ市場：主要企業・種類別/用途別市場規模...Ascites are characterized by excess fluid formation in the abdominal cavity, especially in the peritoneal cavity. It causes the body to lose fluids. When ascites develop due to cancer, it is called malignant peritoneal effusion or malignant ascites.In 2018, the global Malignant Ascites Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025. This report focuses on the global Malignant Ascites Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Malignant Ascites Treatment...

    • ◆H&Iグローバルリサーチのお客様（例）◆